Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 540596 | NSE Symbol : ERIS | ISIN : INE406M01024 | Industry : Pharmaceuticals - Indian - Formulations |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
04-Feb-2025	07-Feb-2025	Interim Dividend	Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2025 inter alia to consider and approve declaration of an interim dividend for the Financial Year 2024-25. Outcome of the Board Meeting (As Per Bse Announcement Dated on 07.02.2025)
29-Jan-2025	04-Feb-2025	Quarterly Results	Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2025 inter alia to consider and approve standalone and consolidated unaudited financial results for the quarter & nine months ended 31 December 2024. Outcome of the Board Meeting held on February 04, 2025 (As Per BSE Announcement dated on 04.02.2025)
22-Oct-2024	25-Oct-2024	Quarterly Results	Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/10/2024 inter alia to consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter and ha Outcome of the Board Meeting held on October 25, 2024 Financial Results for the quarter and half year ended September 30, 2024 (As Per BSE Announcement Dated on 25.10.2024)
30-Jul-2024	02-Aug-2024	Quarterly Results	Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/08/2024 inter alia to consider and approve The Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter Ended June 30 2024. Outcome of the Board meeting Scheme of arrangement between Eris Oaknet Healthcare Private Limited and Eris Lifesciences Limited. (As Per BSE Announcement dated on 02.08.2024)
14-May-2024	21-May-2024	Accounts	Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2024 inter alia to consider and approve the standalone and consolidated audited financial results of the Company for the quarter and year ended March 31 2024. Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2024 ,inter alia, to consider and approve Update on board meeting - Fund Raising (As Per BSE Announcement Dated on 17.05.2024) Financial Results for quarter and year ended 31st March 2024 Issue of Securities Outcome of the Board Meeting (As per BSE Announcement Dated on 21/05/2024)
14-Mar-2024	14-Mar-2024	Acquisitions	Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, in its meeting held today, i.e., 14th March, 2024, inter alia, duly approved/took on record the following: ? Agreement to acquire the Branded Formulations businesses of Biocon Biologics Limited pertaining to the Indian Territory to the extent and in the manner mentioned therein. ? Agreement to acquire 19% equity stake in Swiss Parenterals Limited from the Promoters of the Company. In compliance with the SEBI Circular dated July 13, 2023 bearing reference number SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123, the additional details given under the attached Annexures. The meeting of the Board of Directors commenced at 11:30 A.M. and concluded at 03:05 P.M Acquisition of 19% in stake in Swiss Parenterals Limited
06-Feb-2024	13-Feb-2024	Quarterly Results	Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 inter alia to consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter and nine months ended December 31 2023. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III and SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, we hereby inform you that the Board of Directors of the Company, in their meeting held today, i.e., February 13, 2024, inter alia, duly approved/took on record the following: ? The limited reviewed unaudited Standalone & Consolidated Financial Results for the quarter and nine months ended December 31, 2023; ? Execution of Share Purchase and Shareholders' Agreement for acquisition of 51% equity stake in Swiss Parenterals Limited. ? Issuance of 43,750 8% Secured Redeemable Non-Convertible Debentures having face value of Rs. 1,00,000/- (Rupees One lakh) against the Equity Shares of Swiss Parenterals Limited on Private Placement Basis. Financial Results for the quarter and nine months ended December 31, 2023 Issuance of 43750 8% Secured Redeemable Non-Convertible Debentures (As Per BSE Announcement Dated on 13/02/2024)
01-Nov-2023	08-Nov-2023	Quarterly Results	Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2023 inter alia to consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter and half year ended September 30 2023 Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('LODR') we hereby inform you that the Board of Directors of the Company, in their meeting held today, i.e., November 08, 2023, inter alia, duly approved and took on record the limited reviewed Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2023. The standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2023 are enclosed. The meeting of the Board of Directors commenced at 10:30 A.M. and concluded at 02:10 P.M. This is for your information and record. (As Per BSE Announcement dated on 08.11.2023)
31-Jul-2023	07-Aug-2023	Quarterly Results	Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2023 inter alia to consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter ended 30 June 2023 Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, in their meeting held today, i.e., August 07, 2023, inter alia, duly approved/took on record the following: ? The limited reviewed unaudited Standalone & Consolidated Financial Results for the quarter ended June 30, 2023; ? Convening of 17th Annual General Meeting of the Members of the Company on Monday, September 25, 2023. Please find enclosed limited reviewed standalone and consolidated unaudited financial results for the quarter ended June 30, 2023 The meeting of the Board of Directors commenced at 11:00 A.M. and concluded at 12:50 P.M. This is for your information and record. Outcome of the Board Meeting held today, i.e., August 07, 2023 (As Per BSE Announcement Dated on 07.08.2023)
10-May-2023	17-May-2023	Accounts	Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/05/2023 inter alia to consider and approve the standalone and consolidated audited financial results of the Company for the quarter and year ended 31st March 2023. In accordance with the provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company at their meeting held on 17th May, 2023 has, inter alia, transacted the following business: The Board of Directors duly approved and took on record the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2023. We hereby declare that M/s. Deloitte Haskins & Sells LLP, Chartered Accountants, Statutory Auditors of the Company has issued its Audit Report with unmodified opinion on the Standalone and Consolidated Financial Results of the Company for the year ended 31st March, 2023. The duly signed Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2023 along with the Auditor''s Report are enclosed. The meeting of Board of Directors commenced on 11:00 A.M. and concluded on 02:20 P.M. In accordance with the provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company at their meeting held on 17th May, 2023 has, inter alia, transacted the following business: The Board of Directors duly approved and took on record the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2023. We hereby declare that M/s. Deloitte Haskins & Sells LLP, Chartered Accountants, Statutory Auditors of the Company has issued its Audit Report with unmodified opinion on the Standalone and Consolidated Financial Results of the Company for the year ended 31st March, 2023. The duly signed Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2023 along with the Auditor''s Report are enclosed. The meeting of Board of Directors commenced on 11:00 A.M. and concluded on 02:20 P.M. (As Per BSE Announcement Dated on 17.05.2023)
10-Jan-2023	17-Jan-2023	Quarterly Results	Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/01/2023 inter alia to consider and approve unaudited financial results of the Company for the quarter ended 31 December 2022. Dear Sir/Madam, The Board of Directors of the Company at their meeting held today, i.e., January 17, 2023 duly approved and took on record the limited reviewed Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2022. Please find enclosed standalone and consolidated unaudited financial results for the quarter and nine months ended December 31, 2022. The meeting of the Board of Directors commenced at 11:30 A.M. and concluded at 05:20 P.M. This is for your information and record. Thanking You, (As Per BSE Announcement dated on 17.01.2023)
11-Oct-2022	20-Oct-2022	Quarterly Results	Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/10/2022 inter alia to consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter ended 30 September 2022. Further as informed by us vide letter dated 28 September 2022 the trading window has been already closed from 01 October 2022 and will remain closed till 48 hours after the declaration of financial results of the Company pursuant to SEBI [Prohibition of Insider Trading] Regulations 2015 and Policy on Code of Conduct to Regulate Monitor and Report Trading by its Designated Persons and immediate relatives of Designated Persons of the Company for the purpose of Board Meeting. We hereby inform that the Board of Directors of the Company at their meeting held today i.e. 20 October 2022 has, inter alia, transacted the following business: ? Approved and took on record the limited reviewed Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September 2022. The duly signed Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September 2022 are enclosed herewith. ? The Board considered the re-classification request received from M/s. Shah & Co. The Board reviewed the application received and formed a view that the said request does not prejudice the interests of the Company and its stakeholders in any manner. The Board, therefore, approved the proposal and approved its reference to the stock exchanges for their approval in terms of Regulation 31A of Listing Regulations. (As Per BSE Announcement Dated on 20/10/2022)
29-Jul-2022	05-Aug-2022	Quarterly Results	Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2022 inter alia to consider and approve Dear Sir/Madam NOTICE IS HEREBY given that a Meeting of the Board of Directors of Eris Lifesciences Limited (the Company) is scheduled to be held on 05 August 2022 to inter alia consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter ended 30 June 2022. Further as informed by us vide letter dated 27 June 2022 the trading window has been already closed from 01 July 2022 and will remain closed till 48 hours after the declaration of financial results of the Company pursuant to SEBI [Prohibition of Insider Trading] Regulations 2015 and Policy on Code of Conduct to Regulate Monitor and Report Trading by its Designated Persons and immediate relatives of Designated Persons of the Company for the purpose of Board Meeting. Dear Sir / Madam, It is hereby informed that the Board of Directors shall consider the declaration of interim dividend for the Financial Year 2022-23 at its meeting which is scheduled to be held on 05 August 2022. In the event of the declaration of interim dividend as aforesaid, the proposed record date for the purpose of determining the members eligible for receiving the said interim dividend shall be 16 August 2022. (As Per BSE Announcement Dated on 02.08.2022) Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, in their meeting held today, i.e., 05 August 2022, inter alia, duly approved/took on record the following: Unaudited Standalone Financial Results and Unaudited Consolidated Financial Results for the quarter ended 30 June 2022; Declaration of interim dividend of Rs. 7.35/- (at the rate of 735%) on each fully paid-up equity share of Re. 1/- for the Financial Year 2022-2023; Further, as Communicated in our intimation letter dated 02 August 2022, the record date for determining the eligibility of shareholders for the payment of the interim dividend has been fixed as 16 August 2022. The payment of interim dividend would be made to the eligible shareholders on or before 04 September 2022. Eris Lifesciences Ltd has informed BSE that the Board of Directors of the Company, in their meeting held on August 05, 2022, inter alia, approved/took on record the following : - Declaration of interim dividend of Rs. 7.35/- (at the rate of 735%) on each fully paid-up equity share of Re. 1/- for the Financial Year 2022-2023. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, in their meeting held today, i.e., 05 August 2022, inter alia, duly approved/took on record the following: ? Unaudited Standalone Financial Results and Unaudited Consolidated Financial Results for the quarter ended 30 June 2022; ? Declaration of interim dividend of Rs. 7.35/- (at the rate of 735%) on each fully paid-up equity share of Re. 1/- for the Financial Year 2022-2023; ? Further, as Communicated in our intimation letter dated 02 August 2022, the record date for determining the eligibility of shareholders for the payment of the interim dividend has been fixed as 16 August 2022. The payment of interim dividend would be made to the eligible shareholders on or before 04 September 2022. The Board Meeting commenced at 11:00 A.M. and concluded at 12:35 P.M. Kindly take the above information on your records. (As Per BSE Announcement Dated on 05.08.2022)
15-Jun-2022	15-Jun-2022	Change in Directors	In accordance with the provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we hereby inform you that the Board of Directors of the Company at their meeting held on 15th June, 2022 has, inter alia, transacted the following business: ? Mr. Prashant Gupta's term as an independent director of the company is completing on 29 April 2023. The Board has, subject to approval of the members, approved his reappointment as an independent director for a further period of 5 years starting from 30 April 2023. ? Convening of Annual General Meeting (AGM) of the Members of the Company on Thursday, September 01, 2022.
27-Apr-2022	03-May-2022	Quarterly Results	Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/05/2022 inter alia to consider and approve NOTICE IS HEREBY given that a Meeting of the Board of Directors of Eris Lifesciences Limited (the Company) is scheduled to be held on 3rd May 2022 to inter alia consider and approve the standalone and consolidated audited financial results of the Company for the quarter and year ended 31st March 2022. Further as informed by us vide letter dated 24th March 2022 the trading window has been already closed from 1st April 2022 and will remain closed till 48 hours after the declaration of financial results of the Company pursuant to SEBI [Prohibition of Insider Trading] Regulations 2015 and Policy on Code of Conduct to Regulate Monitor and Report Trading by its Designated Persons and immediate relatives of Designated Persons of the Company for the purpose of Board Meeting. In accordance with the provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company at their meeting held on 3rd May, 2022 has inter alia, transacted the following business: ? Appointment of M/s Ravi Kapoor & Associates, Practicing Company Secretaries, Ahmedabad as the Secretarial Auditor of the Company for the financial year 2022-23. The Brief profile of M/s. Ravi Kapoor & Associates is enclosed herewith. ? Appointment of M/s Kiran J. Mehta & Co., Cost Accountants, as the Cost Auditors of the Company for the financial year 2022-23. The Brief profile of M/s Kiran J Mehta & Co. is enclosed herewith. (As per BSE Announcement Dated on 3/5/2022) The Board of Directors of the Company at their meeting held today i.e. May 03, 2022 duly approved and took on record the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2022. We hereby declare that M/s. Deloitte Haskins & Sells LLP, Chartered Accountants, Statutory Auditors of the Company has issued its Audit Report with unmodified opinion on the Standalone and Consolidated Financial Results of the Company for the year ended 31st March, 2022. Please find enclosed herewith the duly signed Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2022 along with the Auditor''s Report. The Board of Directors of the Company at their meeting held today i.e. May 03, 2022 duly approved and took on record the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2022. We hereby declare that M/s. Deloitte Haskins & Sells LLP, Chartered Accountants, Statutory Auditors of the Company has issued its Audit Report with unmodified opinion on the Standalone and Consolidated Financial Results of the Company for the year ended 31st March, 2022. Please find enclosed herewith the duly signed Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2022 along with the Auditor''s Report. (As Per BSE Announcement Dated on 03.05.2022)

1 2

LOGIN HERE

ERIS Lifesciences Ltd

Board Meeting